The Part B study evaluated 33 patients suffering from severe or very severe alopecia areata. Researchers observed a 35.3% mean reduction in Severity of Alopecia Tool (SALT) scores within the modified intent-to-treat group. Notably, the trial included participants who had previously failed to respond to JAK inhibitors, a common but sometimes limiting standard of care for the condition. The drug, a fully human anti-IL-7Rα antibody, maintained a favorable safety profile with no new signals reported; injection site reactions were identified as the most frequent side effect, though these were generally mild and transient.

Q32 Bio intends to leverage these findings to move into a registration-directed program by the first half of 2027. Dr. Arash Mostaghimi of Harvard Medical School noted that the data suggests the potential for bempikibart to function as a first-line therapy, particularly for patients seeking more durable outcomes. The company plans to present comprehensive results at a future medical meeting as the ongoing follow-up period continues.